19-Aug-2026
No headlines found.
No press releases found.
No news found.
Tema Heart & Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions ("CDC"). GLP-1 (glucagon-like peptide) is a class of drugs that can help manage diabetes and obesity. The Adviser will apply this definition to internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms, development-stage biotechnology companies, diagnostic focused businesses with products used to diagnose and/or treat the aforementioned diseases, medical device companies focused on treatment of the aforementioned diseases, and healthcare service providers with a specific strategic focus on helping treat and manage the aforementioned diseases, each providing they meet the aforementioned revenue test.
Tema Heart & Health ETF trades on the NASDAQ stock market under the symbol HRTS.
As of August 19, 2026, HRTS stock price climbed to $38.87 with 3,136 million shares trading.
HRTS has a market cap of $57.91 million. This is considered a Micro Cap stock.
HRTS has outperformed the market in the last year with a price return of +34.5% while the SPY ETF gained +20.7%. HRTS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +16.9% and +6.7%, respectively, while the SPY returned +4.4% and -0.3%, respectively.
HRTS support price is $37.43 and resistance is $38.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HRTS shares will trade within this expected range on the day.
